1 Scopus citations

Abstract

The FDA has approved CAR-T cell therapy for the treatment of B cell malignancies. Despite the clinical success of CD19 targeted CAR-T, several barriers limit the wider adoption of CAR-based therapies as viable long-term cancer therapies. Many of the barriers that limit the routine use of CAR-T cell therapies stem from utilizing autologous patient T cells as the starting material to generate CAR-T. Here we will describe the limitations of autologous CAR-T, the advantages and hurdles of allogeneic donor CAR-T, the learnings from clinical trials using allogeneic CART19 and discuss the future direction of the field.

Original languageEnglish
Title of host publicationCancer Drug Discovery and Development
PublisherHumana Press Inc.
Pages109-120
Number of pages12
DOIs
StatePublished - 2022

Publication series

NameCancer Drug Discovery and Development
ISSN (Print)2196-9906
ISSN (Electronic)2196-9914

Keywords

  • Allogeneic CAR-T
  • Allogeneic cellular therapy
  • CAR-T
  • CRISPR/Cas9
  • Genetically edited donor derived CAR-T
  • Off the shelf CAR-T
  • TALEN
  • TCRab deleted T cells
  • TRAC
  • UCART123
  • UCART19
  • UCART7
  • Universal CAR-T
  • β2-microglobulin (B2M)

Fingerprint

Dive into the research topics of 'Off-the-Shelf CAR-T'. Together they form a unique fingerprint.

Cite this